Compare ATLO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | MGNX |
|---|---|---|
| Founded | 1903 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 256.8M |
| IPO Year | 2001 | 2013 |
| Metric | ATLO | MGNX |
|---|---|---|
| Price | $31.94 | $4.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 26.2K | ★ 646.7K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | $83.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.96 | $1.30 |
| 52 Week High | $32.16 | $5.08 |
| Indicator | ATLO | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 51.17 |
| Support Level | $28.55 | $3.81 |
| Resistance Level | $32.16 | $4.58 |
| Average True Range (ATR) | 0.71 | 0.21 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 91.97 | 71.52 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.